Request Demo

Last update 05 Sep 2026

Agatolimod

Last update 05 Sep 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

CpG ODN

Synonyms

Agatolimod (USAN), Agatolimod Sodium, CPG B ODN

+ [10]

Target

TLR9

Action

agonists, stimulants

Mechanism

TLR9 agonists(Toll like receptor 9 agonists), Immunostimulants

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

COVID-19

Inactive Indication

Advanced breast cancerAdvanced cancerAdvanced Lung Non-Small Cell Carcinoma+ [15]

Originator Organization

Pfizer Inc.

Noviga Research AB

Active Organization

Noviga Research ABNational Institute of Allergy & Infectious Diseases

Inactive Organization

Pfizer Inc.

Stanford University

Novartis AG

+ [1]

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Structure/Sequence

Boost your research with our RNA technology data.

view full example data

Sequence Code 29253626

Source: *****

Clinical Trials associated with Agatolimod

NCT07221162

/ Active, not recruitingPhase 1IIT

A Phase 1, Open-Label, Safety and Immunogenicity Trial of Boost-2867, an IgG-Fc-RBD Fusion Protein Next Generation SARS-CoV-2 Booster Vaccine, Via Intranasal and Intramuscular Routes in Previously Vaccinated Adults

This phase 1 clinical trial will evaluate the safety, reactogenicity, and immunogenicity of Boost-2867, given intramuscular (IM) with or without adjuvant or intranasal (IN) without adjuvant, as a booster dose to previously vaccinated healthy adults. Each of the study sites will be assigned to enroll either only participants who will receive IM administration (up to 5 sites) or only participants who will receive IN administration (up to 5 sites); no site will administer both IM and IN study product administrations. Within the IM and IN Arms the cohorts will be sequentially enrolled. The study is designed as a non-randomized, open-label, dose-escalation clinical trial evaluating one dose level of Boost-2867 without adjuvant administered IM, three dose levels of Boost-2867 with adjuvant administered IM, and three dose levels of Boost-2867 without adjuvant administered IN. A sample size of 140 participants (20 participants per dose cohort) is anticipated. To evaluate for early safety signals for this first-in-human trial, study product administration of participants enrolled for IM administration and those enrolled for IN administration will proceed in a staged fashion. For Cohorts 1 (IM administration without adjuvant) and 5 (IN administration), which may be enrolled and dosed concurrently, 3 sentinel participants under 50 years of age will be enrolled in each Cohort over at least 2 days. For each of those Cohorts independently, a safety review of halting rules and clinical safety data through at least Day 8 will be conducted by the Protocol Safety Review Team (PSRT) prior to enrollment of the remainder of the cohort. Enrollment, dosing, and safety oversight for IM Cohorts 2, 3, and 4 will proceed in the same fashion as Cohort 1, except that sentinel enrollment need not be spaced over at least 2 days. Similarly, for IN Cohorts 6 and 7, enrollment and safety oversight will proceed in the same fashion as Cohort 5, except that sentinel enrollment need not be spaced over at least 2 days.
The primary objectives are: 1) To evaluate the safety and reactogenicity of a single IM injection of three different antigen dose levels (5, 15, and 50 microgram) of Boost-2867 with Alhydrogel (R) (alum) and CpG 7909 adjuvants, and a single injection of 50 microgram Boost-2867 without adjuvant, in previously vaccinated healthy adults. 2) To evaluate the safety and reactogenicity of a single IN administration of three different antigen dose levels (20, 50, and 125 microgram) of Boost-2867 without adjuvant in previously vaccinated healthy adults.

Start Date05 Dec 2025

Sponsor / Collaborator

National Institute of Allergy & Infectious Diseases

ChiCTR2000036023

/ Not yet recruitingEarly Phase 1IIT

Combined treatment of thermal ablation and CpG 7909/Pembrolizumab for colorectal liver metastases

Start Date01 Sep 2020

Sponsor / Collaborator

Shanghai No. 10 People's Hospital

JPRN-UMIN000017937

/ CompletedPhase 1IIT

WT1 peptide vaccination for patinets with hematological CR after induction chemotherapy

Start Date15 May 2015

Sponsor / Collaborator-

100 Clinical Results associated with Agatolimod

100 Translational Medicine associated with Agatolimod

100 Patents (Medical) associated with Agatolimod

1,154

Literatures (Medical) associated with Agatolimod

31 Dec 2026·OncoImmunology

Sex-based considerations in the choice for a TLR9 or TLR7/8 agonist to arm the sentinel lymph node in early-stage melanoma

Article

Author: van de Ven, Rieneke ; van den Hout, Mari F. C. M. ; Kandiah, Vinitha ; Muijlwijk, Tara ; Labots, Mariette ; van den Eertwegh, Alfons J. M. ; Notohardjo, Jessica C. L. ; de Gruijl, Tanja D. ; Toffoli, Elisa C.

Intradermal delivery of the Toll-like receptor (TLR)-9 agonist agatolimod/CPG7909, prior to sentinel lymph node (SLN) biopsy was previously shown to induce locoregional and systemic immunity, reduce tumor-involved SLN rates, and improve recurrence-free survival in patients with early-stage melanoma. Remarkably, men exhibited superior dendritic cell (DC) maturation. Here, we report on further sex-based differences in the immune response after intradermal administration of CPG7909, which included higher CD80/CD83 expression levels in conventional (c) DC subsets in men's as compared to women's SLN, as well as higher ex-vivo release levels of IL-1β, TNF, and IL-6 (all contributors to cDC activation) and Th1/Th2 cytokines. In an effort to identify a more effective DC-activating therapy for women, we compared the in-vitro effects of CPG7909 with those of the TLR7/8 agonist resiquimod/R848 on SLN single cells from female patients. R848 induced superior cDC subset activation and TNF, IL-6, IL-10, IL-12, IFNγ, and CXCL10 release. Correlation analyses suggested that IFNα, TNF, and IL-6 were key for CPG7909-induced LNR-cDC activation, whereas R848's effect appeared more cytokine-independent. We conclude that combining locally delivered CPG7909 and R848 in early-stage melanoma will ensure full-range DC subset activation and robust pro-inflammatory T-cell responses in melanoma SLN, independent of sex.

01 Nov 2026·JOURNAL OF ETHNOPHARMACOLOGY

Sinomenine restrains the proliferation and hyperactivation of B lymphocytes partly by inhibiting interferon regulatory factor 5

Article

Author: Zhao, Caiping ; Li, Xuexia ; Hu, Huating ; Xu, Peng ; Yu, Lili ; Pan, Hudan ; Peng, Yao ; Chen, Zhengmin ; Li, Rongrong ; Chen, Zhixia ; Wang, Yiyuan ; Li, Runze ; Tian, Ruimin ; Guo, Wanyi ; Xiao, Yao ; He, Jiayan ; Liu, Peiyu ; Liu, Liang ; Quan, Minqi ; Mao, Wei ; Song, Yufei ; Wu, Jiaqi

ETHNOPHARMACOLOGICAL RELEVANCE:

B lymphocytes are central drivers of pathogenic immune responses in autoimmune diseases and represent a promising target for therapeutic intervention. Sinomenine (SIN), a natural alkaloid derived from Sinomenium acutum, exhibits broad immunomodulatory properties and has long been clinically used for treating autoimmune diseases, however, its direct effects on B cells and underlying mechanisms are largely unexplored.

AIM OF THE STUDY:

To investigate the effects of SIN on the proliferation and hyperactivation of B lymphocytes both in vitro and in vivo, and elucidate its therapeutic mechanisms in autoimmune pathologies.

MATERIALS AND METHODS:

Firstly, SIN was examined for its ability against lipopolysaccharides (LPS) or CpG oligodeoxynucleotide (CpG) induced B cell proliferation and hyperactivity. Then, the effects of SIN regulating B cell subsets and antibody response were studied in pristane-induced lupus and keyhole limpet hemocyanin (KLH)-immunized murine models. Furthermore, transcriptomics, small molecule-protein interaction assay (SPIA) and a series of validation experiments (including Western blotting, immunofluorescence, cellular thermal shift assay (CETSA), surface plasmon resonance (SPR), and flow cytometry) were performed to identify the key mechanisms involved.

RESULTS:

For the first time, our research revealed the significant inhibitory efficacy of SIN on B cell proliferation induced by LPS or CpG. Moreover, SIN significantly reduced CD69 expression, and attenuated IL-6 and IL-10 hypersecretion. Notably, SIN exerted a better inhibitory effect against CpG-mediated activation compared to LPS-induced responses. In the early immune response of pristane-induced lupus model, both SIN and prednisone significantly decreased the spleen coefficient and the proportion of CD19⁺CD69⁺ B cell subsets. In the KLH immunization model, SIN alleviated splenomegaly, lowered serum levels of IgG and IgM, and reduced the cell counts of B220+ cells and proportion of plasma cells (B220^lowCD19-CD138+). Integration of transcriptomic analyses and in vitro verification revealed SIN's regulatory effects on cell cycle, the PI3K-AKT signaling pathway, along with its marked suppression of NF-κB protein activation following both LPS and CpG stimulation. In response to CpG stimulation, SIN also significantly decreased the protein levels of p-STAT3 and STAT3. Further research by SPIA identified the downregulation of interferon regulatory factor 5 (IRF5) by SIN. This effect was then corroborated by Western blot, immunofluorescence, molecular docking, CETSA, and SPR analyses, confirming SIN as a novel modulator of IRF5. Moreover, pharmacological inhibition of IRF5 by IRF5-IN-1 markedly significantly attenuated the proliferation and hyperactivation of B cells following LPS or CpG challenge, implying the critical role of IRF5 in B cells.

CONCLUSIONS:

Collectively, our findings suggest that SIN restrains the proliferation and hyperactivation of B lymphocytes via inhibiting IRF5 and modulating the PI3K-Akt, STAT3, and NFκB signaling cascades. These results uncover a previously unrecognized mechanism of B cell regulation and support a potential therapeutic approach for autoimmune diseases involving pathogenic B cells by SIN.

01 Jun 2026·Drug Delivery and Translational Research

Intralesional injection of CpG ODNs complexed with glatiramer acetate mitigates systemic cytokine toxicities and synergistically advances checkpoint blockade efficacy

Article

Author: Forrest, Marcus Laird ; Gong, Huan ; Abdelaziz, Moustafa M ; Wu, Xiaoqing ; Griffin, J Daniel ; Groer, Chad E ; Berkland, Cory J ; Xu, Liang ; Li, Mengyue

PD-L1/PD-1 checkpoint inhibitors (CPIs) are mainstream agents for cancer immunotherapy, but the prognosis is unsatisfactory in solid tumor patients lacking preexisting T-cell reactivity. Adjunct therapy strategies including the intratumoral administration of immunostimulants aim to address this limitation. CpG oligodeoxynucleotides (ODNs), TLR9 agonists that can potentiate adaptive immunity, have been widely investigated to tackle PD-L1/PD-1 resistance, but clinical success has been hindered by inconsistent efficacy and immune-related toxicities caused by systemic exposure. Here, we utilized glatiramer acetate (GA), the FDA-approved, lysine-rich polypeptides to complex CpG into polycationic nanoparticles (R4B) and investigated the safety and antitumor efficacy of CpG ODNs in the murine CT26 colorectal carcinoma model. In a maximum tolerated dose study, repetitive R4B treatment displayed comparable antitumor efficacy to CpG alone treatment within a dose range from 15 µg to 150 µg while significantly attenuating systemic proinflammatory cytokine IL-6 release. A pharmacokinetic and biodistribution analysis confirmed that R4B localized and gradually released CpG around the lesions within 96 h while 'naked' CpG quickly diffused from the injection site. Genome-wide transcriptome analysis validated that R4B treatment activated prominent TLR9-driven immune system responses in both lesions and spleens. In a CT26 multiple tumor model, intratumoral administration of R4B generated systemic immune efficacy, evidenced by an abscopal effect on untreated tumors. Notably, R4B treatment accomplished these effects with mitigated systemic proinflammatory cytokines when compared with CpG alone. We further discovered that combining R4B with anti-PD-1 treatment led to the most pronounced effects on tumor growth and longest benefits to survival time. Our investigation into possible mechanisms underlying this phenomenon included increased recruitment of cytotoxic CD8⁺ T cells and natural killer (NK) cells to the tumor microenvironments and the reversal of PD-L1/PD-1 axis inhibition. In summary, these results warrant further investigation for safely improving clinical responses in CPI-resistant solid tumor patients with localized CpG ODN therapy.

News (Medical) associated with Agatolimod

22 Oct 2025

·www.prnewswire.com

ACM Biolabs Reports Favorable Safety Signals and Early Pharmacodynamics from Intramuscular Administration of ACM-CpG in Patients with Advanced Solid Tumors

SINGAPORE, Oct. 22, 2025 /PRNewswire/ -- ACM Biolabs, a clinical-stage biotechnology company developing next-generation nanoparticle-based immunotherapies, today announced encouraging early clinical findings from its ongoing Phase 1 study of ACM-CpG, a TLR9 agonist formulated with ACM's proprietary polymersome platform through a strategic collaboration with the National Cancer Centre Singapore (NCCS). Preclinical experiments show that the ACM nanoparticle formulation fundamentally alters CpG's mechanism of action, enabling myeloid modulation through comprehensive TLR9 engagement in immunologically "cold" tumors. The ongoing Phase 1 trial (NCT06587295) [i] is enrolling patients with advanced solid tumors at NCCS to assess the safety, tolerability, and pharmacodynamic effects of ACM-CpG. Early clinical data indicate that these preclinical findings are translating into humans. In patients with advanced solid tumors, intramuscular administration of ACM-CpG - at weekly or biweekly doses as low as 0.25mg CpG – has demonstrated robust systemic immune activation as evidenced through immune biomarker data. The therapy shows a highly favorable safety and tolerability profile and to date, no dose-limiting toxicities have been observed. "TLR9 has long been recognized as a validated immunologic target, but its therapeutic potential has been limited by delivery and safety limitations," said Dr. Madhavan Nallani, CEO of ACM Biolabs. "Our intramuscular nanoparticle delivery enables systemic immune activation with an excellent safety profile, creating opportunities not only for combination approaches but also for targeted monotherapy in patient populations with few treatment options. Over time, this platform can also support additional routes of administration allowing us to tailor treatment strategies to diverse tumor settings and address significant unmet medical needs." "The safety profile and clear pharmacodynamic activity we have observed so far are very encouraging, with two out of the three patients enrolled at the 0.25mg dose level having ongoing disease control for eight months with monotherapy alone." said Dr. Amit Jain, Senior Consultant, Division of Medical Oncology, National Cancer Centre Singapore. "We look forward to exploring ways to optimize its delivery and maximize its therapeutic potential for patients with advanced cancers." The collaboration is supported in part by funding from Singapore's Industry Alignment Fund – Pre-Positioning (IAF-PP), which fosters strategic collaborations between industry and research institutes. This study is evaluating ACM-CpG in patients with advanced head and neck, lung, bladder, and kidney cancers and is designed to establish proof of mechanism to support global clinical development. About ACM Biolabs Pte Ltd ACM Biolabs is headquartered in Singapore, with subsidiaries in Basel, Switzerland, and Sydney, Australia. It is a clinical-stage biotechnology company developing targeted vaccines and immunotherapies using its proprietary polymer-lipid hybrid nanoparticle delivery platform. The company's pipeline includes candidates across oncology, infectious diseases, and inflammation, with a focus on precision immune modulation and next-generation drug delivery. SOURCE ACM Biolabs WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

ImmunotherapyPhase 1

22 Oct 2025

·acmbiolabs.com

ACM Biolabs Reports Favorable Safety Signals and Early Pharmacodynamics from Intramuscular Administration of ACM-CpG in Patients with Advanced Solid Tumors

Singapore, 22nd October 2025 – ACM Biolabs, a clinical-stage biotechnology company developing next-generation nanoparticle-based immunotherapies, today announced encouraging early clinical findings from its ongoing Phase 1 study of ACM-CpG, a TLR9 agonist formulated with ACM’s proprietary polymersome platform through a strategic collaboration with the National Cancer Centre Singapore (NCCS). Preclinical experiments show that the ACM nanoparticle formulation fundamentally alters CpG’s mechanism of action, enabling myeloid modulation through comprehensive TLR9 engagement in immunologically “cold” tumors. The ongoing Phase 1 trial (NCT06587295)i is enrolling patients with advanced solid tumors at NCCS to assess the safety, tolerability, and pharmacodynamic effects of ACM-CpG. Early clinical data indicate that these preclinical findings are translating into humans. In patients with advanced solid tumors, intramuscular administration of ACM-CpG – at weekly or biweekly doses as low as 0.25mg CpG – has demonstrated robust systemic immune activation as evidenced through immune biomarker data. The therapy shows a highly favorable safety and tolerability profile and to date, no dose-limiting toxicities have been observed. “TLR9 has long been recognized as a validated immunologic target, but its therapeutic potential has been limited by delivery and safety limitations,” said Dr. Madhavan Nallani, CEO of ACM Biolabs. “Our intramuscular nanoparticle delivery enables systemic immune activation with an excellent safety profile, creating opportunities not only for combination approaches but also for targeted monotherapy in patient populations with few treatment options. Over time, this platform can also support additional routes of administration allowing us to tailor treatment strategies to diverse tumor settings and address significant unmet medical needs.” “TLR9 has long been recognized as a validated immunologic target, but its therapeutic potential has been limited by delivery and safety limitations,” said Dr. Madhavan Nallani, CEO of ACM Biolabs. “Our intramuscular nanoparticle delivery enables systemic immune activation with an excellent safety profile, creating opportunities not only for combination approaches but also for targeted monotherapy in patient populations with few treatment options. Over time, this platform can also support additional routes of administration allowing us to tailor treatment strategies to diverse tumor settings and address significant unmet medical needs.” “The safety profile and clear pharmacodynamic activity we have observed so far are very encouraging, with two out of the three patients enrolled at the 0.25mg dose level having ongoing disease control for eight months with monotherapy alone.” said Dr. Amit Jain, Senior Consultant, Division of Medical Oncology, National Cancer Centre Singapore. “We look forward to exploring ways to optimize its delivery and maximize its therapeutic potential for patients with advanced cancers.” “The safety profile and clear pharmacodynamic activity we have observed so far are very encouraging, with two out of the three patients enrolled at the 0.25mg dose level having ongoing disease control for eight months with monotherapy alone.” said Dr. Amit Jain, Senior Consultant, Division of Medical Oncology, National Cancer Centre Singapore. “We look forward to exploring ways to optimize its delivery and maximize its therapeutic potential for patients with advanced cancers.” The collaboration is supported in part by funding from Singapore’s Industry Alignment Fund – Pre-Positioning (IAF-PP), which fosters strategic collaborations between industry and research institutes. This study is evaluating ACM-CpG in patients with advanced head and neck, lung, bladder, and kidney cancers and is designed to establish proof of mechanism to support global clinical development. About ACM Biolabs Pte Ltd ACM Biolabs is headquartered in Singapore, with subsidiaries in Basel, Switzerland, and Sydney, Australia. It is a clinical-stage biotechnology company developing targeted vaccines and immunotherapies using its proprietary polymer-lipid hybrid nanoparticle delivery platform. The company’s pipeline includes candidates across oncology, infectious diseases, and inflammation, with a focus on precision immune modulation and next-generation drug delivery. Media contacts Dr Peter Moran Email: peter.moran@acmbiolabs.com General Inquiries: BD@acmbiolabs.com About ACM Biolabs Pte Ltd ACM Biolabs is headquartered in Singapore, with subsidiaries in Basel, Switzerland, and Sydney, Australia. It is a clinical-stage biotechnology company developing targeted vaccines and immunotherapies using its proprietary polymer-lipid hybrid nanoparticle delivery platform. The company’s pipeline includes candidates across oncology, infectious diseases, and inflammation, with a focus on precision immune modulation and next-generation drug delivery. Media contacts Dr Peter Moran Email: peter.moran@acmbiolabs.com General Inquiries: BD@acmbiolabs.com ACM Biolabs is headquartered in Singapore, with subsidiaries in Basel, Switzerland, and Sydney, Australia. It is a clinical-stage biotechnology company developing targeted vaccines and immunotherapies using its proprietary polymer-lipid hybrid nanoparticle delivery platform. The company’s pipeline includes candidates across oncology, infectious diseases, and inflammation, with a focus on precision immune modulation and next-generation drug delivery. Media contacts Dr Peter Moran Email: peter.moran@acmbiolabs.com General Inquiries: BD@acmbiolabs.com 1 https://www.clinicaltrials.gov/study/NCT06587295

ImmunotherapyPhase 1

28 Aug 2025

·liddspharma.com

LIDDS AB (publ) Interim Report January – June 2025

April – June 2025 Net sales amounted to 0 (0) KSEK The operating result for the period was -836 (-2 391) KSEK The net result was -733 (-2 398) KSEK corresponding to earnings per share of -0,01 (-0.02) SEK Cash flow from operating activities amounted to -1 594 (-2 938) KSEK Cash and cash equivalents amounted to 2 350 (8 009) KSEK January – June 2025 Net sales amounted to 0 (0) KSEK The operating result for the period was -2 091 (-2 392) KSEK The net result was -2 044 (-2 404) KSEK corresponding to earnings per share of -0,01 (-0.02) SEK Cash flow from operating activities amounted to -2 333 (-3 002) KSEK Significant events January – June 2025 On April 2, the board of directors decided to cease further development of the project areas Nanodotax, Nanoimod and NOV 202. Taking into account the principle of prudence, the board of directors, decided on April 10 to write down the book values of all intangible assets in LIDDS and Noviga as of 2024-12-31. This decision resulted in a deviation for the annual report compared to the published year-end report for 2024. Due to the reasons to believe that the company’s equity was less than on-half of the registered share capital, the board of directors decided to prepare a balance sheet for liquidation purpose on April 22. The balance sheet for liquidation purpose prepared and reviewed by the company’s auditor showed that the equity was less than half of the registered share capital and therefore the board of directors decided on April 24 to call a first control meeting. At the annual general meeting, at the same time first control meeting, on May 28, it was decided that the company will continue its operations and not be liquidated. CEO Statement During the second quarter, the company has continued to focus on the commercialisation of the three projects Nanoimod, Nanodotax and NOV 202, as well as exploring interest in the company’s listing on First North. So far, these efforts have not yet resulted in any concrete successes. The quarter has also been characterised by extensive work on finalising the annual report, holding the annual general meeting, and managing the situation where the company’s equity was found to be less than half of the share capital. Following the decision at the first control meeting to continue operations and not initiate liquidation, the company now has eight months before the question of potential liquidation needs to be reconsidered. Mats WikingCEO and CFO The interim report is available on the company’s website https://liddspharma.com/en/investors/financial-reports/ For additional information, please contact Mats Wiking, CEO and CFOPhone: +46 (0)70 620 04 00E-mail: mats.wiking@liddspharma.com Daniel Lifveredson, Chairman of the BoardTelefon: +46 (0) 70-916 21 01Email: d.li@excore.com LIDDS’ Certified Adviser is Redeye AB LIDDS in brief: LIDDS is a Swedish pharmaceutical company focused on the development of oncology drugs. LIDDS has a proprietary drug delivery technology, NanoZolid®, on which several projects are based. With NanoZolid, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release and with minimal negative side-effects. In addition to these projects, LIDDS develops proprietary drug candidate NOV202 that have shown very good results in pre-clinical studies. The company is listed on Nasdaq First North Growth market. Attachments LIDDS Interim Report Q2 2025

Financial Statement

100 Deals associated with Agatolimod

External Link

KEGG	Wiki	ATC	Drug Bank
D08841	Agatolimod	-	DB15018

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Lung Non-Small Cell Carcinoma	Phase 3	United States	Pfizer Inc.	01 Nov 2005
Advanced Lung Non-Small Cell Carcinoma	Phase 3	China	Pfizer Inc.	01 Nov 2005
Advanced Lung Non-Small Cell Carcinoma	Phase 3	Australia	Pfizer Inc.	01 Nov 2005
Advanced Lung Non-Small Cell Carcinoma	Phase 3	Austria	Pfizer Inc.	01 Nov 2005
Advanced Lung Non-Small Cell Carcinoma	Phase 3	Belgium	Pfizer Inc.	01 Nov 2005
Advanced Lung Non-Small Cell Carcinoma	Phase 3	Brazil	Pfizer Inc.	01 Nov 2005
Advanced Lung Non-Small Cell Carcinoma	Phase 3	Canada	Pfizer Inc.	01 Nov 2005
Advanced Lung Non-Small Cell Carcinoma	Phase 3	Cyprus	Pfizer Inc.	01 Nov 2005
Advanced Lung Non-Small Cell Carcinoma	Phase 3	Czechia	Pfizer Inc.	01 Nov 2005
Advanced Lung Non-Small Cell Carcinoma	Phase 3	France	Pfizer Inc.	01 Nov 2005

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00199836 (CTgov)	Phase 1	Neoplasms	14	NY-ESO-1b peptide plus CpG 7909 and Montanide® ISA-51	ltntrcsosx = eycwfvuglu wzxmbcyqig (epbucayqfl, wxxkcvpjye - xnmvfrcuhw) View more	-	15 Jul 2021
AACR2017	Phase 2	Melanoma Adjuvant	-	Saline	ayclohzbvs(gyzwohajts) = jlgljbmvco sugfmpxalr (uilhziqoev, 21 - 71)	Positive	01 Jul 2017
NCT00880581 (CTgov)	Phase 2	Indolent B-Cell Non-Hodgkin Lymphoma	30	Local radiotherapy+PF-3512676	lzywygvyxi = ncrvokbgup xhxictpvbi (xsaielornn, goxxrvzgde - zczhkhehrn) View more	-	14 Mar 2017
NCT00824733 (CTgov)	Phase 2	Locally advanced breast cancer \| Metastatic breast cancer	6	Correlative Studies+PF03512676+Trastuzumab	gstfhvletp(mdicyfhnuf) = dhjjukvmwx rpwvvycrla (mlxglrkgyl, lgbndopzqi - dxtmkejkcw) View more	-	14 Jan 2016
SITC2015	Phase 2	Melanoma Adjuvant	62	GM-CSF (3 μg/kg)	gyeabrpmhc(drfpqbxwpk) = at a median follow-up of 79 months, this translated into a significantly longer recurrence-free survival (RFS) in the CpG-treated group (p=0.010) grvrxefynl (ymhhtrxiqm )	Positive	04 Nov 2015
SITC2015	Phase 2	Melanoma Adjuvant	62	CpG-B (PF-3512676/CpG7909, 8 mg)		Positive	04 Nov 2015
NCT00185965 (CTgov)	Phase 1/2	Mycosis Fungoides	30	CPG 7909 (Lymphoma, B-cell Low-grade (BCL))	ywmnnsxipr = bvdtlqpojo pqfuzpbgtl (ivvwtibbyr, cgzwcxceli - bpnkqenkpe) View more	-	01 Aug 2014
NCT00185965 (CTgov)	Phase 1/2	Mycosis Fungoides	30	CPG 7909 (Mycosis Fungoides (MF))	ywmnnsxipr = xtuwpdosey pqfuzpbgtl (ivvwtibbyr, wspoigvbjj - fdmjjntkdu) View more	-	01 Aug 2014
Pubmed \| J Immunother	Phase 1	Metastatic melanoma Adjuvant	22	Vaccination with MART-1, gp100, and Tyrosinase peptides + PF-3512676 + GM-CSF	efjwwouecp(bbkvwmakuj) = iujjdgxvyz ftnugyzxij (jsujfrrojm, 11.3 - ∞)	-	01 May 2012
NCT00984763 (Pubmed \| PLoS One)	Phase 1	Malaria	5	AMA1-C1/Alhydrogel+CPG 7909 (AMA1/C1-Alhydrogel+CPG 7909)	wfcnsnwhgy(duiwfdjzlh): Pearson r = -0.93 (95% CI, -0.99 to -0.25), P-Value = 0.02	-	22 Jul 2011
NCT00984763 (Pubmed \| PLoS One)	Phase 1	Malaria	5	AMA1-C1/Alhydrogel+CPG 7909 (Unvaccinated controls)		-	22 Jul 2011
AACR2011	Not Applicable	Melanoma	12	Vaccination with MART-1 (27-35), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) peptides given in-oil-adjuvant with TLR-9 agonist PF-3512676 and GMCSF	onxkziwxdc(bvfgsoplit) = wrfpdfgunl dafxpljmvz (qhimfthosj ) View more	-	15 Apr 2011
Pubmed \| J Am Acad Dermatol	Phase 1	Cutaneous T-Cell Lymphoma	28	PF-3512676 (CPG 7909)	fwdejeqllh(yhbqetnphf) = tuxgpqrnmi odongakbjn (xyxtiehoom )	Positive	01 Dec 2010

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis